Publications

2023

Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.

American journal of clinical and experimental urology.11(2):185-193[DOI] .[PMID] 37168940.

PubMed·Publisher's Site

2023

Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of > 60,000 men.

International urology and nephrology.55(2):295-300[DOI] 10.1007/s11255-022-03363-6.[PMID] 36171482.

5 citations·PubMed·Publisher's Site

2022

Combination therapy in metastatic castration sensitive prostate cancer: A Systematic review and network meta-analysis.

Indian journal of urology : IJU : journal of the Urological Society of India.38(3):220-226[DOI] 10.4103/iju.iju_402_21.[PMID] 35983120.

PubMed·Publisher's Site

2021

An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model.

Journal of endourology.35(4):409-416[DOI] 10.1089/end.2020.0739.[PMID] 32962442.

30 citations·PubMed·Publisher's Site

2021

Intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy: a meta-analysis, cumulative analysis, and systematic review.

Journal of robotic surgery.15(3):321-333[DOI] 10.1007/s11701-020-01174-4.[PMID] 33222043.

17 citations·PubMed·Publisher's Site

2021

Pathology grade influences competing mortality risks in elderly men with prostate cancer.

Urologic oncology.39(8):493.e1-493.e7[DOI] 10.1016/j.urolonc.2020.12.004.[PMID] 33353870.

1 citations·PubMed·Publisher's Site

2020

A Systematic Review and Meta-Analysis of Methods Used to Reduce Infectious Complications Following Transrectal Prostate Biopsy.

Urology.144():21-27[DOI] 10.1016/j.urology.2020.06.005.[PMID] 32569659.

3 citations·PubMed·Publisher's Site

2020

Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.

Urologic oncology.38(11):826-834[DOI] 10.1016/j.urolonc.2020.03.022.[PMID] 32605736.

24 citations·PubMed·Publisher's Site

2019

Characterization of Novel Murine and Human PDAC Cell Models: Identifying the Role of Intestine Specific Homeobox Gene ISX in Hypoxia and Disease Progression.

Translational oncology.12(8):1056-1071[DOI] 10.1016/j.tranon.2019.05.002.[PMID] 31174057.

3 citations·PubMed·Publisher's Site

2019

Predictive and targeting value of IGFBP-3 in therapeutically resistant prostate cancer.

American journal of clinical and experimental urology.7(3):188-202[DOI] .[PMID] 31317059.

13 citations·PubMed·Publisher's Site

2019

Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen‐dependent and castration‐resistant prostate cancer cells

The Prostate.79(2):140-150[DOI] 10.1002/pros.23719.[PMID] 30280407.

22 citations·PubMed·Publisher's Site

2018

BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models.

Clinical cancer research : an official journal of the American Association for Cancer Research.24(24):6421-6432[DOI] 10.1158/1078-0432.CCR-18-1394.[PMID] 30087142.

23 citations·PubMed·Publisher's Site

2017

Androgen receptor splice variants and prostate cancer: From bench to bedside.

Oncotarget.8(11):18550-18576[DOI] 10.18632/oncotarget.14537.[PMID] 28077788.

89 citations·PubMed·Publisher's Site

2017

Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.

Oncotarget.8(45):78507-78519[DOI] 10.18632/oncotarget.19659.[PMID] 29108245.

19 citations·PubMed·Publisher's Site

2016

Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.

The Prostate.76(12):1067-77[DOI] 10.1002/pros.23190.[PMID] 27271795.

10 citations·PubMed·Publisher's Site

2016

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Clinical cancer research : an official journal of the American Association for Cancer Research.():-[DOI] 10.1158/1078-0432.CCR-16-0137.[PMID] 27458247.

4 citations·PubMed·Publisher's Site

2016

Mitochondrial dysfunction-mediated apoptosis resistance associates with defective heat shock protein response in African-American men with prostate cancer.

British journal of cancer.114(10):1090-100[DOI] 10.1038/bjc.2016.88.[PMID] 27115471.

23 citations·PubMed·Publisher's Site

2016

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Oncotarget.7(39):64447-64470[DOI] 10.18632/oncotarget.10901.[PMID] 27487144.

116 citations·PubMed·Publisher's Site

2016

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.

International journal of biological sciences.12(4):409-26[DOI] 10.7150/ijbs.14090.[PMID] 27019626.

29 citations·PubMed·Publisher's Site

2015

Commentary on "Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies)".

Asian journal of andrology.17(1):160-[DOI] 10.4103/1008-682X.143305.[PMID] 25475665.

PubMed·Publisher's Site

2014

Androgen receptor mutations and polymorphisms in African American prostate cancer.

International journal of biological sciences.10(6):643-51[DOI] 10.7150/ijbs.8974.[PMID] 24948877.

25 citations·PubMed·Publisher's Site

2014

Biological and clinical significance of androgens and androgen receptor in prostate cancer.

International journal of biological sciences.10(6):652-3[DOI] 10.7150/ijbs.9576.[PMID] 24948878.

0 citations·PubMed·Publisher's Site

2014

Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer.

Cancer research.74(8):2362-73[DOI] 10.1158/0008-5472.CAN-13-3058.[PMID] 24509905.

82 citations·PubMed·Publisher's Site

2014

Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT.

International journal of biological sciences.10(8):834-45[DOI] 10.7150/ijbs.9406.[PMID] 25076860.

22 citations·PubMed·Publisher's Site

2014

Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.

Cell reports.8(5):1461-74[DOI] 10.1016/j.celrep.2014.07.053.[PMID] 25176644.

220 citations·PubMed·Publisher's Site

2014

Identification of novel GRM1 mutations and single nucleotide polymorphisms in prostate cancer cell lines and tissues.

PloS one.9(7):e103204-[DOI] 10.1371/journal.pone.0103204.[PMID] 25062106.

12 citations·PubMed·Publisher's Site

2014

ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.

International journal of cancer.135(11):2493-506[DOI] 10.1002/ijc.28919.[PMID] 24752651.

33 citations·PubMed·Publisher's Site

2014

Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.

Oncotarget.5(3):824-40[DOI] .[PMID] 24583788.

46 citations·PubMed·Publisher's Site

2013

Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.

Carcinogenesis.34(8):1737-46[DOI] 10.1093/carcin/bgt126.[PMID] 23576568.

30 citations·PubMed·Publisher's Site

2013

BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.

PloS one.8(1):e52993-[DOI] 10.1371/journal.pone.0052993.[PMID] 23308129.

24 citations·PubMed·Publisher's Site

2013

Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.

International journal of biological sciences.9(7):728-42[DOI] 10.7150/ijbs.6475.[PMID] 23983606.

59 citations·PubMed·Publisher's Site

2013

Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer.

Asian journal of andrology.15(2):212-3[DOI] 10.1038/aja.2012.145.[PMID] 23314660.

22 citations·PubMed·Publisher's Site

2013

Glutamate, glutamate receptors, and downstream signaling pathways.

International journal of biological sciences.9(9):948-59[DOI] 10.7150/ijbs.6426.[PMID] 24155668.

191 citations·PubMed·Publisher's Site

2013

Polycyclic aromatic hydrocarbons-induced ROS accumulation enhances mutagenic potential of T-antigen from human polyomavirus JC.

Journal of cellular physiology.228(11):2127-38[DOI] 10.1002/jcp.24375.[PMID] 23558788.

26 citations·PubMed·Publisher's Site

2013

Reduced mitochondrial DNA content associates with poor prognosis of prostate cancer in African American men.

PloS one.8(9):e74688-[DOI] 10.1371/journal.pone.0074688.[PMID] 24086362.

41 citations·PubMed·Publisher's Site

2013

Resveratrol depletes mitochondrial DNA and inhibition of autophagy enhances resveratrol-induced caspase activation.

Mitochondrion.13(5):493-9[DOI] 10.1016/j.mito.2012.10.010.[PMID] 23088850.

29 citations·PubMed·Publisher's Site

2012

Regulators of gene expression as biomarkers for prostate cancer.

American journal of cancer research.2(6):620-57[DOI] .[PMID] 23226612.

23 citations·PubMed·Publisher's Site

2012

Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research.18(21):5888-901[DOI] 10.1158/1078-0432.CCR-12-1308.[PMID] 23072969.

99 citations·PubMed·Publisher's Site

2012

Serum prosaposin levels are increased in patients with advanced prostate cancer.

The Prostate.72(3):253-69[DOI] 10.1002/pros.21427.[PMID] 21630292.

22 citations·PubMed·Publisher's Site

2011

Aberrant DNA methylation and prostate cancer.

Current genomics.12(7):486-505[DOI] 10.2174/138920211797904061.[PMID] 22547956.

77 citations·PubMed·Publisher's Site

2011

DNA methylome and the complexity of discovering prostate cancer biomarkers.

Asian journal of andrology.13(5):661-2[DOI] 10.1038/aja.2011.90.[PMID] 21725333.

2 citations·PubMed·Publisher's Site

2011

Genetic and epigenetic changes in human prostate cancer.

Iranian Red Crescent medical journal.13(2):80-98[DOI] .[PMID] 22737441.

13 citations·PubMed·Publisher's Site

2010

Androgen receptor signaling and mutations in prostate cancer.

Asian journal of andrology.12(5):639-57[DOI] 10.1038/aja.2010.89.[PMID] 20711217.

99 citations·PubMed·Publisher's Site

2010

Comment on "Effect of transferred NK4 gene on proliferation, migration, invasion, and apoptosis of human prostate cancer DU145 cells" by Dan Yue et al. in Asian Journal of Andrology.

Asian journal of andrology.12(3):444-6[DOI] 10.1038/aja.2010.26.[PMID] 20400970.

PubMed·Publisher's Site

2010

Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer.

Asian journal of andrology.12(3):336-43[DOI] 10.1038/aja.2010.5.[PMID] 20173765.

13 citations·PubMed·Publisher's Site

2010

Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.

PloS one.5(7):e11475-[DOI] 10.1371/journal.pone.0011475.[PMID] 20628607.

29 citations·PubMed·Publisher's Site

2010

Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation.

Journal of immunology (Baltimore, Md. : 1950).185(3):1894-902[DOI] 10.4049/jimmunol.1000646.[PMID] 20610652.

125 citations·PubMed·Publisher's Site

2010

Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion.

Molecular cancer.9():30-[DOI] 10.1186/1476-4598-9-30.[PMID] 20132547.

30 citations·PubMed·Publisher's Site

2009

Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains.

Journal of virology.83(9):4227-35[DOI] 10.1128/JVI.02578-08.[PMID] 19244333.

13 citations·PubMed·Publisher's Site

2008

Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.

Journal of cellular biochemistry.104(6):2272-85[DOI] 10.1002/jcb.21786.[PMID] 18481277.

9 citations·PubMed·Publisher's Site

2007

Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.

Molecular endocrinology (Baltimore, Md.).21(3):613-24[DOI] .[PMID] 17192406.

33 citations·PubMed·Publisher's Site

2007

Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.

Journal of cellular biochemistry.101(3):631-41[DOI] .[PMID] 17171640.

11 citations·PubMed·Publisher's Site

2007

Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).

The Prostate.67(2):178-89[DOI] .[PMID] 17044040.

21 citations·PubMed·Publisher's Site

2007

Survivin is not only a death encounter but also a survival protein for invading tumor cells.

Frontiers in bioscience : a journal and virtual library.12():1260-70[DOI] .[PMID] 17127378.

28 citations·PubMed·Publisher's Site

2006

Pleomorphic adenoma of the trachea in an 8-year-old boy: a case report.

Journal of pediatric surgery.41(8):e23-6[DOI] .[PMID] 16863832.

16 citations·PubMed·Publisher's Site

2005

Amplification and overexpression of prosaposin in prostate cancer.

Genes, chromosomes & cancer.44(4):351-64[DOI] .[PMID] 16080200.

39 citations·PubMed·Publisher's Site

2005

Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.

Urologic oncology.23(3):163-7[DOI] .[PMID] 15907715.

2 citations·PubMed·Publisher's Site

2005

Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells.

Asian journal of andrology.7(2):147-58[DOI] .[PMID] 15897971.

25 citations·PubMed·Publisher's Site

2004

Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells.

The Prostate.61(2):114-23[DOI] .[PMID] 15305334.

20 citations·PubMed·Publisher's Site

2004

Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.

Molecular cancer.3():31-[DOI] .[PMID] 15548330.

34 citations·PubMed·Publisher's Site

2004

Stem cells and prostate cancer.

Clinical prostate cancer.3(1):11-2[DOI] .[PMID] 15279683.

PubMed·Publisher's Site

2001

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways.

Proceedings of the National Academy of Sciences of the United States of America.98(7):4089-94[DOI] .[PMID] 11259649.

80 citations·PubMed·Publisher's Site

2000

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Cancer research.60(2):342-9[DOI] .[PMID] 10667586.

144 citations·PubMed·Publisher's Site

1999

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Molecular and cellular biology.19(9):5902-12[DOI] .[PMID] 10454537.

165 citations·PubMed·Publisher's Site

1998

Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.

Oncogene.17(21):2691-700[DOI] .[PMID] 9840933.

33 citations·PubMed·Publisher's Site

1998

The mutationally activated Met receptor mediates motility and metastasis.

Proceedings of the National Academy of Sciences of the United States of America.95(24):14417-22[DOI] .[PMID] 9826715.

200 citations·PubMed·Publisher's Site

1997

Met and hepatocyte growth factor/scatter factor expression in human gliomas.

Cancer research.57(23):5391-8[DOI] .[PMID] 9393765.

296 citations·PubMed·Publisher's Site

1996

Expression of serotonin receptors in human fetal astrocytes and glioma cell lines: a possible role in glioma cell proliferation and migration.

Brain research. Molecular brain research.41(1-2):1-7[DOI] .[PMID] 8883928.

52 citations·PubMed·Publisher's Site

1995

Adhesion of human glioma cell lines to fibronectin, laminin, vitronectin and collagen I is modulated by gangliosides in vitro.

Cell adhesion and communication.3(1):27-43[DOI] .[PMID] 7749720.

43 citations·PubMed·Publisher's Site

1995

Extracellular matrix proteins inhibit proliferation, upregulate migration and induce morphological changes in human glioma cell lines.

European journal of cancer (Oxford, England : 1990).31A(3):375-80[DOI] .[PMID] 7540403.

62 citations·PubMed·Publisher's Site

1995

Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells in vitro.

Molecular and chemical neuropathology.24(2-3):121-35[DOI] .[PMID] 7632317.

35 citations·PubMed·Publisher's Site

1995

Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro.

International journal of cancer.63(3):450-4[DOI] .[PMID] 7591247.

92 citations·PubMed·Publisher's Site

1995

Synergism between growth-factors in the control of glioma cell-proliferation, migration and invasion in-vitro.

International journal of oncology.6(5):1079-85[DOI] .[PMID] 21556643.

15 citations·PubMed·Publisher's Site

1994

Cell surface gangliosides are involved in the control of human glioma cell invasion in vitro.

Neuroscience letters.177(1-2):44-6[DOI] .[PMID] 7824179.

37 citations·PubMed·Publisher's Site

Show More